Investors drove shares in Rxi Pharmaceuticals Corp. (NASDAQ:RXII) up as high as $4.30 Friday after the company reported that intravitreal injection of RXI-109, its experimental RNA interference-based therapy, reduced connective tissue growth factor (CTFG) protein levels in an animal study, showing its potential to fight retinal and corneal scarring as a result of injury or disease.